Beyfortus approved in China for the prevention of RSV disease in infants

eAwazMedicine

London – AstraZeneca and Sanofi’s Beyfortus (nirsevimab), a long-acting monoclonal antibody, has been approved in China for the prevention of respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI) in neonates and infants entering or during their first RSV season.1 Beyfortus is anticipated to be available during the upcoming 2024-2025 RSV season. Beyfortus is the first approved preventive option to protect against RSV in a …

Health Ministers on overdose crisis

eAwazHealth

Amendment request granted to British Columbia for the subsection 56(1) exemption from Controlled Drugs and Substances Act. Law enforcement in B.C. will have the authority to seize drugs, and arrest or charge for personal possession of under 2.5 grams in certain locations frequented by children and youth Ottawa – Canada is facing an unrelenting and tragic toxic drug and overdose …